Authors:
RAINOV NG
DOBBERSTEIN KU
SENAESTEVES M
HERRLINGER U
KRAMM CM
PHILPOT RM
HILTON J
CHIOCCA EA
BREAKEFIELD XO
Citation: Ng. Rainov et al., NEW PRODRUG ACTIVATION GENE-THERAPY FOR CANCER USING CYTOCHROME-P450 4B1 AND 2-AMINOANTHRACENE 4-IPOMEANOL/, Human gene therapy, 9(9), 1998, pp. 1261-1273
Citation: Ma. Potter et al., SUPPRESSION OF IMMUNOLOGICAL RESPONSE AGAINST A TRANSGENE PRODUCT DELIVERED FROM MICROENCAPSULATED CELLS, Human gene therapy, 9(9), 1998, pp. 1275-1282
Authors:
WANG L
WITHERINGTON C
KING A
GERLACH WL
CARR A
PENNY R
COOPER D
SYMONDS G
SUN LQ
Citation: L. Wang et al., PRECLINICAL CHARACTERIZATION OF AN ANTI-TAT RIBOZYME FOR THERAPEUTIC APPLICATION, Human gene therapy, 9(9), 1998, pp. 1283-1291
Authors:
KOSAI KI
FINEGOLD MJ
THIHUYNH BT
TEWSON M
OU CN
BOWLES N
WOO SLC
SCHWALL RH
DARLINGTON GJ
Citation: Ki. Kosai et al., RETROVIRUS-MEDIATED IN-VIVO GENE-TRANSFER IN THE REPLICATING LIVER USING RECOMBINANT HEPATOCYTE GROWTH-FACTOR WITHOUT LIVER-INJURY OR PARTIAL-HEPATECTOMY, Human gene therapy, 9(9), 1998, pp. 1293-1301
Authors:
BOWMAN LC
GROSSMANN M
RILL D
BROWN M
ZHONG WY
ALEXANDER B
LEIMIG T
COUSTANSMITH E
CAMPANA D
JENKINS J
WOODS D
BRENNER M
Citation: Lc. Bowman et al., INTERLEUKIN-2 GENE-MODIFIED ALLOGENEIC-TUMOR CELLS FOR TREATMENT OF RELAPSED NEUROBLASTOMA, Human gene therapy, 9(9), 1998, pp. 1303-1311
Authors:
FREYTAG SO
ROGULSKI KR
PAIELLI DL
GILBERT JD
KIM JH
Citation: So. Freytag et al., A NOVEL 3-PRONGED APPROACH TO KILL CANCER-CELLS SELECTIVELY - CONCOMITANT VIRAL, DOUBLE SUICIDE GENE, AND RADIOTHERAPY, Human gene therapy, 9(9), 1998, pp. 1323-1333
Authors:
IMRO MA
DELLABONA P
MANICI S
HELTAI S
CONSOGNO G
BELLONE M
RUGARLI C
PROTTI MP
Citation: Ma. Imro et al., HUMAN-MELANOMA CELLS TRANSFECTED WITH THE B7-2 COSTIMULATORY MOLECULEINDUCE TUMOR-SPECIFIC CD8(-LYMPHOCYTES IN-VITRO() CYTOTOXIC T), Human gene therapy, 9(9), 1998, pp. 1335-1344
Citation: E. Sanjose et al., RETROVIRAL VECTOR-MEDIATED EXPRESSION IN PRIMARY HUMAN T-CELLS OF AN ENDOPLASMIC RETICULUM-RETAINED CD4 CHIMERA INHIBITS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION, Human gene therapy, 9(9), 1998, pp. 1345-1357
Authors:
DELLAMBRA E
VAILLY J
PELLEGRINI G
BONDANZA S
GOLISANO O
MACCHIA C
ZAMBRUNO G
MENEGUZZI G
DELUCA M
Citation: E. Dellambra et al., CORRECTIVE TRANSDUCTION OF HUMAN EPIDERMAL STEM-CELLS IN LAMININ-5-DEPENDENT JUNCTIONAL EPIDERMOLYSIS-BULLOSA, Human gene therapy, 9(9), 1998, pp. 1359-1370
Citation: Sk. Arya et al., HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 LENTIVIRUS VECTORS FOR GENE-TRANSFER - EXPRESSION AND POTENTIAL FOR HELPER VIRUS-FREE PACKAGING, Human gene therapy, 9(9), 1998, pp. 1371-1380
Citation: Rm. Zwacka et al., REDOX GENE-THERAPY PROTECTS HUMAN IB-3 LUNG EPITHELIAL-CELLS AGAINST IONIZING RADIATION-INDUCED APOPTOSIS, Human gene therapy, 9(9), 1998, pp. 1381-1386
Citation: F. Paillard, EPSTEIN-BARR-VIRUS VECTORS FOR THE TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED CANCERS, Human gene therapy, 9(8), 1998, pp. 1119-1120
Authors:
TURNER JG
TAN J
CRUCIAN BE
SULLIVAN DM
BALLESTER OF
DALTON WS
YANG NS
BURKHOLDER JK
YU H
Citation: Jg. Turner et al., BROADENED CLINICAL UTILITY OF GENE GUN-MEDIATED, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR CDNA-BASED TUMOR-CELL VACCINES AS DEMONSTRATED WITH A MOUSE MYELOMA MODEL, Human gene therapy, 9(8), 1998, pp. 1121-1130
Citation: S. Kenney et al., GENE-THERAPY STRATEGIES FOR TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS - COMPARISON OF 2 DIFFERENT EPSTEIN-BARR VIRUS-BASED VECTORS, Human gene therapy, 9(8), 1998, pp. 1131-1141
Citation: Dk. Hoganson et al., TOXIN GENE-MEDIATED GROWTH-INHIBITION OF LUNG ADENOCARCINOMA IN AN ANIMAL-MODEL OF PLEURAL MALIGNANCY, Human gene therapy, 9(8), 1998, pp. 1143-1156
Citation: T. Wu et al., MURINE BONE-MARROW EXPRESSING THE NEOMYCIN RESISTANCE GENE HAS NO COMPETITIVE DISADVANTAGE ASSESSED IN-VIVO, Human gene therapy, 9(8), 1998, pp. 1157-1164
Authors:
LONG ZF
LI LP
GROOMS T
LOCKEY C
NADER K
MYCHOVSKY I
MUELLER S
BURIMSKI I
RYAN P
KIKUCHI G
ENNIST D
MARCUS S
OTTO E
MCGARRITY G
Citation: Zf. Long et al., BIOSAFETY MONITORING OF PATIENTS RECEIVING INTRACEREBRAL INJECTIONS OF MURINE RETROVIRAL VECTOR PRODUCER CELLS, Human gene therapy, 9(8), 1998, pp. 1165-1172
Authors:
LAHIJANI R
DUHON M
LUSBY E
BETITA H
MARQUET M
Citation: R. Lahijani et al., QUANTITATION OF HOST-CELL DNA CONTAMINATE IN PHARMACEUTICAL-GRADE PLASMID DNA USING COMPETITIVE POLYMERASE-CHAIN-REACTION AND ENZYME-LINKED-IMMUNOSORBENT-ASSAY, Human gene therapy, 9(8), 1998, pp. 1173-1180
Authors:
WHITE SJ
PAGE SM
MARGARITIS P
BROWNLEE GG
Citation: Sj. White et al., LONG-TERM EXPRESSION OF HUMAN CLOTTING FACTOR-IX FROM RETROVIRALLY TRANSDUCED PRIMARY HUMAN KERATINOCYTES IN-VIVO, Human gene therapy, 9(8), 1998, pp. 1187-1195
Authors:
DAVIS BR
SAITTA FP
BAUER G
BUNNELL BA
MORGAN RA
SCHWARTZ DH
Citation: Br. Davis et al., TARGETED TRANSDUCTION OF CD34(-EXPRESSING RETROVIRUS YIELDS PARTIAL ANTI-HIV PROTECTION OF PROGENY MACROPHAGES() CELLS BY TRANSDOMINANT NEGATIVE REV), Human gene therapy, 9(8), 1998, pp. 1197-1207
Citation: Js. Han et al., A METHOD OF LIMITED REPLICATION FOR THE EFFICIENT IN-VIVO DELIVERY OFADENOVIRUS TO CANCER-CELLS, Human gene therapy, 9(8), 1998, pp. 1209-1216